Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL635989 | 0.83 | SLC6A4 (0.56) | SLC6A4CYP1A2CYP2D6CYP2C19AOC3 | |
| SCHEMBL6325819 | 0.80 | SLC6A4 (0.54) | SLC6A4CYP1A2CYP2D6CYP2C19AOC3 | |
| SCHEMBL636064 | 0.80 | SLC6A4 (0.53) | SLC6A4CYP1A2CYP2D6CYP2C19AOC3 | |
| SCHEMBL3946088 | 0.80 | SLC6A4 (0.53) | SLC6A4CYP1A2CYP2D6CYP2C19AOC3 | |
| SCHEMBL636098 | 0.78 | SLC6A4 (0.51) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL637387 | 0.77 | SLC6A4 (0.44) | SLC6A4CYP1A2CYP2D6CYP2C19AOC3 | |
| SCHEMBL6327948 | 0.73 | SLC6A4 (0.57) | SLC6A4CYP1A2CYP2D6CYP2C19IDO1 | |
| SCHEMBL1152830 | 0.72 | AOC3 (0.44) | SLC6A4CYP1A2CYP2D6CYP2C19AOC3 | |
| SCHEMBL1152832 | 0.72 | AOC3 (0.44) | SLC6A4CYP1A2CYP2D6CYP2C19AOC3 | |
| Hydrochloric Acid SCHEMBL10276302 | 0.71 | SLC6A4 (0.65) | SLC6A4CYP1A2CYP2D6CYP2C19AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20180079741-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9809569-B2 | Process for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-07 | — | — | US | disclosed |
| US-20170081305-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-3118192-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | disclosed |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| EP-1927596-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2008-06-04 | — | — | EP | disclosed |
| EP-1904454-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | Nycomed GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| US-7326784-B2 | Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives | ALTANA PHARMA AG (DE) | 2008-02-05 | — | — | US | disclosed |
| WO-2007141253-A1 | PROCESS FOR THE PRODUCTION OF INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC IMIDAZOPYRIDINES | NYCOMED GMBH (DE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070117786-A1 | Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives | ALTANA PHARMA AG (DE) | 2007-05-24 | — | — | US | disclosed |
| WO-2006136552-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1697358-A1 | INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC DIHYDROPYRANO -IMIDAZO -PYRIDINES DERIVATIVES | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058894-A1 | INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC DIHYDROPYRANO -IMIDAZO -PYRIDINES DERIVATIVES | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081305-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | DHPS, QDPR, DPYD | SLC6A4 2573/4885CYP1A2 28/4885CYP2D6 29/4885 |
| US-10988469-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | SLC6A4 1615/4885CYP1A2 1113/4885CYP2D6 484/4885 |
| US-20070117786-A1 | Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives | CYP1A1, CYP3A4, CYP19A1 | SLC6A4 4110/4885CYP1A2 5/4885CYP2D6 19/4885 |
| US-20180079741-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | DHPS, QDPR, DPYD | SLC6A4 2573/4885CYP1A2 28/4885CYP2D6 29/4885 |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | SLC6A4 1615/4885CYP1A2 1113/4885CYP2D6 484/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | SLC6A4 1615/4885CYP1A2 1113/4885CYP2D6 484/4885 |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | MVD, C5, C1S | SLC6A4 3807/4885CYP1A2 45/4885CYP2D6 4/4885 |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | CYP1B1, CYP1A1, CYP3A4 | SLC6A4 3334/4885CYP1A2 7/4885CYP2D6 23/4885 |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | SLC6A4 1615/4885CYP1A2 1113/4885CYP2D6 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.